Information Provided By: 
Fly News Breaks for July 29, 2016
GILD
Jul 29, 2016 | 07:31 EDT
As noted earlier, Argus downgraded Gilead to Hold from Buy. Analyst David Toung is worried about slowing sales of the company's HCV products and predicts that its gross margins will be pressured, partly due to lower revenue per patient in the U.S.
News For GILD From the Last 2 Days
GILD
Apr 22, 2024 | 07:19 EDT
Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.
